Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 12.66 USD 1.28%
Market Cap: 327.1m USD
Have any thoughts about
Eton Pharmaceuticals Inc?
Write Note

Eton Pharmaceuticals Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eton Pharmaceuticals Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Eton Pharmaceuticals Inc
NASDAQ:ETON
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Short-Term Debt
$2B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Short-Term Debt
$205m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Short-Term Debt
$8.2B
CAGR 3-Years
104%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eton Pharmaceuticals Inc
Glance View

Market Cap
327.1m USD
Industry
Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
13.52 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Eton Pharmaceuticals Inc's Short-Term Debt?
Short-Term Debt
0 USD

Based on the financial report for Sep 30, 2024, Eton Pharmaceuticals Inc's Short-Term Debt amounts to 0 USD.

Back to Top